Royalty Report: Drugs, Antibody, Therapeutic – Collection: 273384

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Antibody
  • Therapeutic
  • Vaccine
  • Drug Discovery
  • Arthritis

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 273384

License Grant
Sellers hereby grants to Buyer an exclusive, limited to the Anthrax Field, worldwide, perpetual license under the Technology to Develop and Commercialize Products intended for use in the Anthrax Field, with the right to grant sublicenses.
License Property
Technology means Know-How or intellectual property owned, or licensed, by Seller reasonably necessary or useful in connection with the development or commercialization of pharmaceutical products incorporating human monoclonal antibodies.

The AVP Anthrax Patents constitute all patents and patent applications owned by Sellers necessary or useful for the exploitation of the Product and the conduct of the Product Line Operations.

Licensed Product means the Product as licensed or approved by any applicable Regulatory Authority or any product Developed or Commercialized under a sublicense of the rights granted under the Asset License in this Agreement.

Field of Use
Buyer received a limited exclusive license to use Sellers's proprietary Xenerexâ„¢ Technology platform to develop future human monoclonal antibodies targeted against Bacillus anthracis.

IPSCIO Record ID: 248394

License Grant
The Licensor, government organization of England, grants the Licensee of England a nonexclusive worldwide license to use the Intellectual Property to develop, make, or have made, use, keep, sell, offer to sell, import and export Licensed Products, and to develop, make, have made, and use Anthrax Vaccine for the purpose of Licensor exercising the rights and licenses granted to Licensor with respect to Licensed Product.
License Property
Anthrax Vaccine shall mean protective antigen from Bacillus anthracis (anthrax) which is produced using recombinant technology.

Anthrax Vaccine Dose shall mean the quantity of a formulation containing Anthrax Vaccine given to an individual in a single immunization.

Licensed Product shall mean an Anthrax Vaccine Dose the manufacture, use, sale, keeping, importing or exporting of which would, in the absence of the license granted under this Agreement, constitute an infringement of the Patents or that uses other Intellectual Property.

The patent is for Expression System (Anthrax Immuuogenic Polypeptide), a UK Priority Patent Application.

Recombinant Bacillus Anthracis (Anthrax) Protective Antigen Vaccine containing Alum

The patent covers MOD Case P1454 Expression System.

Field of Use
These agreements allow for the licensing of certain patents and technology necessary to perform development of the rPA and rYP programs as required under the Company’s government contracts with the NIAID.

PharmAthene is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons.

IPSCIO Record ID: 289246

License Grant
Licensor grants the Licensee of China an exclusive, non-transferable, perpetual license in the field of Therapeutic usage in order to develop and conduct clinical trials to achieve Chinese FDA (SFDA) approval of the rabbit anti-TNFalpha monoclonal antibody compounds. Under these rights, Licensor grants both the manufacturing and distribution rights of anti-TNFalpha monoclonal antibody therapeutics covered under the intellectual properties rights owned by Licensor.
License Property
Licensor utilizes a proprietary and patented technology in the development and production of Rabbit Monoclonal Antibodies (RabMAb technology).

Licensor has developed a panel of 50 novel anti-TNFalpha rabbit monoclonal antibodies that are highly potent compared with Remicade and Humira in in-vitro assays.

Licensor will provide Humanized Rabbit anti-TNFalpha monoclonal antibodies to Licensee.

Field of Use
The field is for commercializing anti-TNFalpha monoclonal antibodies to be used as therapeutic agents.  Anti-TNFalpha therapies are effective in treating Rheumatoid arthritis, Psoriasis, Psoriatic arthritis, Ankylosing spondylis and Crohns diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.